Is Visby Medical profitable in 2026?

Visby Medical does not publicly disclose audited financials. ZoomInfo estimates revenue near $87.7 million as of July 2026, but that figure comes from a third party data broker, not the company, so profitability cannot be confirmed from public sources.

Has Visby Medical had layoffs?

No layoff announcements have been reported as of July 2026. Headcount trackers show the company still hiring, with one aggregator citing 7.2 percent year over year headcount growth, though exact staff counts vary by source.

Could AI replace Visby Medical's diagnostic tests?

Visby's product is a physical single use PCR device, not software, so AI cannot directly replicate it. Its device reads results via colorimetric LED chemistry through a smartphone app, not machine learning image interpretation, per FDA filing K253971.

Who is Visby Medical's biggest competitor?

Visby's closest peer, Lucira Health, was wound down by owner Pfizer in Q1 2025 after failing the same at home disposable PCR business model. Larger incumbents Abbott, Cepheid, Roche and QIAGEN have not yet shipped a competing instrument free disposable PCR product.

Who owns Visby Medical?

Visby Medical is privately held and venture backed, led by founder and CEO Adam de la Zerda. Investors include Catalio Capital Management, ND Capital, Cedars Sinai Medical Center, Pitango Ventures, and John Doerr, per the June 17, 2025 Series F announcement.

What was Visby Medical previously called?

Visby Medical was founded in 2012 under the name Click Diagnostics before rebranding, according to CB Insights company records dated July 2, 2026.

United States · United States

Visby Medical

Maker of instrument-free, single-use PCR tests for STIs and respiratory viruses.

Losing its protection

Assessed 29 July 2026 · Evidence as of 29 July 2026

The structural protection is eroding.

On the recordSince 29 July 2026 · Checkable from H2 2026 · Every call on the record Checkpoint: FDA decision on the Men's Sexual Health Test, submitted May 2025

The call

Visby has real FDA firsts, but still has to prove disposable PCR tests can turn a profit, the same problem that sank Lucira Health in 2025.

Visby Medical sells single-use PCR test devices that people can use at home to check for sexually transmitted infections and viruses like flu. The company has FDA approvals and patents that protect its design, which is genuinely hard to copy quickly. However, the real problem is not competition from rivals like Abbott or Cepheid, it is whether Visby can sell these tests cheaply enough to make money when each one costs money to manufacture and ship. Lucira Health tried the exact same business model and shut down in early 2025 despite being backed by Pfizer, which shows that having a big parent company does not fix the core math problem. The one thing that could change the picture is if Visby proves that people will keep buying tests regularly through partnerships with delivery apps and clinics, and if the company can do this without losing money on each sale.

Why

AI pressure: AI symptom-triage tools (e.g. Google AMIE-style systems). AI triage could nudge low-risk patients away from testing, but antibiotic rules still require molecular confirmation before treatment. Could AI do the core job? Unlikely.

Bigger players: Abbott (ID NOW/BinaxNOW). Abbott already sells disposable point-of-care tests and could build a rival instrument-free PCR device, but has not announced one. Could a giant copy it? Probably.

What protects it. FDA De Novo clearance, CLIA waivers, and a 44-patent device design that a rival must replicate before it can compete.

What would change this call

FDA decision on Visby's Men's Sexual Health Test submission. Clearance would expand product line; delay or rejection would signal regulatory or execution risk.
Terms of Visby's next funding round after the June 2025 Series F. A flat or down-round would echo the Lucira pattern of unproven unit economics.
Abbott or Cepheid announcing a disposable, instrument-free at-home PCR product. Would show a major incumbent entering Visby's core category directly.

Key numbers

$65M Series F led by Catalio Capital (2025-06-17)
$1B+ valuation set in 2022 Series E extension (2022-06-30)
44 patents cover its single-use PCR device (2026-07-02)

Named risks

Unit economics of single use at home disposable PCR remain unproven at consumer prices. Severity: high
Lucira Health precedent shows institutional backing did not solve category economics, ending in a 2025 wind down. Severity: high
Abbott or Cepheid could ship a competing instrument free disposable PCR format. Severity: medium
Next funding round could be flat or down absent proven margins, echoing the Lucira pattern. Severity: medium
Men's Sexual Health Test FDA clearance still pending as of July 2026, delaying product line expansion. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Lucira Health	gaining on	Lucira, the closest peer using an identical at home disposable PCR model, was wound down by Pfizer in Q1 2025
Abbott	contesting	Abbott already sells disposable point of care tests like BinaxNOW and is not structurally blocked from entering at home disposable PCR
Cue Health	gaining on	Cue Health, another single use diagnostic hardware maker, filed for bankruptcy in June 2024
Cepheid, Roche, QIAGEN	contesting	These incumbents run instrument based razor blade models and have not yet shipped a competing instrument free disposable PCR as of 2026

Questions people ask

Is Visby Medical profitable in 2026?: Visby Medical does not publicly disclose audited financials. ZoomInfo estimates revenue near $87.7 million as of July 2026, but that figure comes from a third party data broker, not the company, so profitability cannot be confirmed from public sources.
Has Visby Medical had layoffs?: No layoff announcements have been reported as of July 2026. Headcount trackers show the company still hiring, with one aggregator citing 7.2 percent year over year headcount growth, though exact staff counts vary by source.
Could AI replace Visby Medical's diagnostic tests?: Visby's product is a physical single use PCR device, not software, so AI cannot directly replicate it. Its device reads results via colorimetric LED chemistry through a smartphone app, not machine learning image interpretation, per FDA filing K253971.
Who is Visby Medical's biggest competitor?: Visby's closest peer, Lucira Health, was wound down by owner Pfizer in Q1 2025 after failing the same at home disposable PCR business model. Larger incumbents Abbott, Cepheid, Roche and QIAGEN have not yet shipped a competing instrument free disposable PCR product.
Who owns Visby Medical?: Visby Medical is privately held and venture backed, led by founder and CEO Adam de la Zerda. Investors include Catalio Capital Management, ND Capital, Cedars Sinai Medical Center, Pitango Ventures, and John Doerr, per the June 17, 2025 Series F announcement.
What was Visby Medical previously called?: Visby Medical was founded in 2012 under the name Click Diagnostics before rebranding, according to CB Insights company records dated July 2, 2026.

Timeline

2026-07FDA clears first at home multi viral PCR test for Flu and COVID-19
2026-05-12Launches Safe Access Program with RAINN for free at home STI tests
2026-04-16Announces same day prescribing partnership with telehealth provider Wisp
2025-12Announces DTC distribution via Everlywell, DoorDash, GoPuff and Google Cloud partnership
2025-06-17Closes Series F of up to $65 million led by Catalio Capital Management
2025-03-28Women's Sexual Health Test granted FDA De Novo classification
2025-02Respiratory Health Test for Flu A/B and COVID-19 gets FDA clearance and CLIA waiver
2025Pfizer winds down Lucira Health, the closest peer in at home molecular diagnostics
2023-03Second generation Sexual Health Test (Chlamydia, Gonorrhea, Trichomoniasis) gets 510(k) clearance
2022-06-30Series E extended by $35 million to over $135 million total at $1 billion plus valuation

Revision history

29 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

American Airlines Group Wayfair Safe Superintelligence Inc.